What is Tremfya (Psoriasis) Tremfya?
Tremfya is a prescription medication that is used to treat psoriasis. It is classified as a biologic drug and is administered via injection. The active ingredient in Tremfya is guselkumab, which works by blocking specific proteins in the body that cause inflammation.
Psoriasis is an autoimmune disorder that affects the skin and can cause a variety of symptoms, including redness, scaling, itching, and thickening of the skin. It can be a chronic condition, and there is currently no cure.
Tremfya is specifically designed to target the underlying cause of psoriasis by blocking the IL-23 protein, which is believed to be a key contributor to the development and formation of psoriasis. By preventing this protein from causing inflammation and other symptoms, Tremfya can help to reduce the severity of psoriasis and improve the overall quality of life for patients.
Tremfya is typically administered once every 8 weeks, although the exact dosing schedule may vary depending on the severity of a patient's condition and other factors. It is important to follow the dosing instructions provided by your healthcare provider to ensure that you receive the maximum benefit from the medication.
As with any medication, there may be side effects associated with Tremfya. Common side effects can include injection site reactions, upper respiratory tract infections, and headaches. It is important to discuss any potential side effects with your healthcare provider before beginning treatment.
Overall, Tremfya is a valuable tool in the treatment of psoriasis, and has been shown to be effective in reducing the severity of symptoms for many patients. If you are struggling with psoriasis, talk to your healthcare provider about whether Tremfya may be an appropriate option for you.
Frequently Asked Questions about tremfya (psoriasis) tremfya
Tremfya is a monoclonal antibody that blocks a certain protein in the body that can cause inflammation and other immune responses. Tremfya is used to treat moderate to severe plaque psoriasis in adults. Tremfya is also used to treat active psoriatic arthritis in adults.
TREMFYA® is a single-dose 100 mg injection taken under the skin at weeks 0 and 4, and then every 8 weeks. That's only 6 doses per year after 2 starter doses. TREMFYA® is intended for use under the guidance and supervision of physicians.
Tremfya 100 mg solution for injection in pre-filled pen Each pre-filled pen contains 100 mg of guselkumab in 1 mL solution. Guselkumab is a fully human immunoglobulin G1 lamda (IgG1λ) monoclonal antibody (mAb) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
TREMFYA® (guselkumab) About Janssen Biotech, Inc.
Subcutaneous Solution
| Quantity | Per unit | Price |
|---|
| 1 milliliter | $13,921.94 | $13,921.94 |
Common side effects of Tremfya include:
- upper respiratory infections,
- headache,
- injection site reactions,
- joint pain,
- diarrhea,
- gastroenteritis (nausea, vomiting, diarrhea, cramps, and fever),
- tinea infections (athlete's foot, ringworm, jock itch), and.
- herpes simplex infections.
The list price of TREMFYA® is $13,212.19 every 8 weeks for the 100 mg Syringe or 100 mg One-Press injector as of March 2023. Eligible commercial patients can save with the TREMFYA withMe Savings Program.
TREMFYA® is not a steroid. TREMFYA® is a biologic that works to target an overactive immune system, a possible cause of plaque psoriasis. It blocks the action of interleukin-23, or IL-23, one of the proteins that may play a role in plaque psoriasis.
Tremfya can still increase a person's risk of infection or cause reactivation of tuberculosis; however, the risk for serious infection is low (0.3%) and similar to a placebo (a medicine with no active ingredient in it).
Generic Name: guselkumab
This medication is used to treat plaque psoriasis and psoriatic arthritis. Guselkumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural substance in your body (interleukin-23) that may cause inflammation and swelling.
Guselkumab (Tremfya) is available on the NHS as a possible treatment for plaque psoriasis in adults if: the psoriasis is severe and affects quality of life and.
Tremfya contains the active ingredient guselkumab, and it's available only as a brand-name biologic drug. It doesn't come in a biosimilar version. A biosimilar medication is a drug that's similar to a brand-name biologic drug (the parent drug). Also, biosimilars tend to cost less than brand-name medications.
Janssen said the list price for guselkumab is £2,250 per 100mg. NICE is already assessing the drug and based on current timelines, Janssen anticipates a decision by June next year. Janssen also plans to submit a dossier to the Scottish Medicine Consortium in December 2017.
Guselkumab (Tremfya) is available on the NHS as a possible treatment for plaque psoriasis in adults if: the psoriasis is severe and affects quality of life and.
Blauvelt et al (2017)9 evaluated the efficacy and safety of TREMFYA compared to placebo and adalimumab in patients with moderate to severe plaque PsO. Through week 16, there were no reports of weight gain in the TREMFYA and placebo groups. Weight gain was reported in 1/333 (0.3%) patients in the adalimumab group.
Janssen said the list price for guselkumab is £2,250 per 100mg. NICE is already assessing the drug and based on current timelines, Janssen anticipates a decision by June next year. Janssen also plans to submit a dossier to the Scottish Medicine Consortium in December 2017.
